O33.F Glycorex Transplantation AB (publ)

Healthcare Biotechnology Frankfurt Exchange
0.1575 EUR
Close of Nov 12, 2026
0.0206 0.1940
Market cap
EUR 11.9M
P/E
-
P/B
4.83x
ROE
-58.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is O33.F undervalued?

Graham number

The Graham number of Glycorex Transplantation AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Glycorex Transplantation AB (publ) fundamental analysis

No fundamental analysis for Glycorex Transplantation AB (publ) yet.

Glycorex Transplantation AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Glycorex Transplantation AB (publ)

Glycorex Transplantation AB (publ), a medical technology company, research, develops, manufactures, markets, and sells products in the field of organ transplantation or related areas. It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood. The company's principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, liver, lung, and stem cell transpl…

Full company profile